Cargando…

Ghrelin: A New Incretin Enhancer Therapy?

Detalles Bibliográficos
Autores principales:	DeMarco, Vincent G., Sowers, James R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2015
Materias:	Commentaries
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4407859/ https://www.ncbi.nlm.nih.gov/pubmed/25908874 http://dx.doi.org/10.2337/db14-1871

Ejemplares similares

Incretin Therapy and Islet Pathology: A Time for Caution
por: Kahn, Steven E.
Publicado: (2013)

Incretin action on bone: An added benefit?
por: Ma, Ronald C W, et al.
Publicado: (2015)

The Links of Ghrelin to Incretins, Insulin, Glucagon, and Leptin After Bariatric Surgery
por: Skuratovskaia, Daria, et al.
Publicado: (2021)

Incretins in the ICU: is insulin on its way out?
por: Kovalaske, Michelle A, et al.
Publicado: (2009)

Visfatin and resistin: Mediators of the pleiotropic effects of incretins?
por: Nakashima, Eitaro
Publicado: (2012)

Incretin Therapy and Pancreatic Pathologies: Background Pathology Versus Drug-Induced Pathology in Rats
por: Egan, Josephine M., et al.
Publicado: (2014)

The D-Day of ghrelin
por: Tong, Jenny, et al.
Publicado: (2016)

New Thoughts in an Old Player: Role of Nitrite in the Treatment of Ischemic Revascularization
por: Jia, Guanghong, et al.
Publicado: (2014)

Cardiovascular safety trials of incretin‐based drugs: What do they mean?
por: Yabe, Daisuke, et al.
Publicado: (2016)

Incretin-based therapies
por: Stonehouse, Anthony H, et al.
Publicado: (2012)

Glycogen Synthase Kinase-3β and Cathepsin B in Diabetic Endothelial Progenitor Cell Dysfunction: An Old Player Finds a New Partner
por: Muniyappa, Ranganath, et al.
Publicado: (2014)

Is ghrelin a glucagon‐like peptide‐1 secretagogue?
por: Ueno, Hiroaki, et al.
Publicado: (2015)

Renoprotective effects of incretin‐based drugs: A novel pleiotropic effect of dipeptidyl peptidase‐4 inhibitor
por: Kodera, Ryo, et al.
Publicado: (2015)

Incretin-Based Therapies for the Treatment of Type 2 Diabetes: Evaluation of the Risks and Benefits
por: Drucker, Daniel J., et al.
Publicado: (2010)

Role of TRIB3 in Diabetic and Overnutrition-Induced Atherosclerosis
por: Sowers, James R.
Publicado: (2012)

Incretin concept revised: The origin of the insulinotropic function of glucagon‐like peptide‐1 – the gut, the islets or both?
por: Yabe, Daisuke, et al.
Publicado: (2017)

Therapy in the Early Stage: Incretins
por: Cernea, Simona, et al.
Publicado: (2011)

Caveolin-1 in Cardiovascular Disease: A Double-Edged Sword
por: Jia, Guanghong, et al.
Publicado: (2015)

Application of a Novel Curcumin Analog in the Management of Diabetic Cardiomyopathy
por: Ren, Jun, et al.
Publicado: (2014)

Pancreatitis Associated With Incretin-Based Therapies
por: Iyer, Shridhar N., et al.
Publicado: (2013)

Endothelial Insulin and IGF-1 Receptors: When Yes Means NO
por: Muniyappa, Ranganath, et al.
Publicado: (2012)

Interaction of Islet α-Cell and β-Cell in the Regulation of Glucose Homeostasis in HI/HA Syndrome Patients With the GDH(H454Y) Mutation
por: Jia, Guanghong, et al.
Publicado: (2014)

Targeting CITED2 for Angiogenesis in Obesity and Insulin Resistance
por: Jia, Guanghong, et al.
Publicado: (2016)

Increased Fibro-Adipogenic Progenitors and Intramyocellular Lipid Accumulation in Obesity-Related Skeletal Muscle Dysfunction
por: Jia, Guanghong, et al.
Publicado: (2019)

Incretins in the Therapy of Diabetic Kidney Disease
por: Przezak, Agnieszka, et al.
Publicado: (2021)

Socioeconomic aspects of incretin-based therapy
por: Karagiannis, Thomas, et al.
Publicado: (2023)

Implications for Glucose Measures in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study
por: Whaley-Connell, Adam, et al.
Publicado: (2014)

Endothelium-Derived Hyperpolarizing Factors: A Potential Therapeutic Target for Vascular Dysfunction in Obesity and Insulin Resistance
por: Jia, Guanghong, et al.
Publicado: (2016)

Final Answer: Ghrelin Can Suppress Insulin Secretion in Humans, but Is It Clinically Relevant?
por: Meyer, Christian
Publicado: (2010)

Incretin-based therapies: new treatments for type 2 diabetes in the new millennium
por: Khoo, Joan, et al.
Publicado: (2009)

Uncovering a Mineralocorticoid Receptor–Dependent Adipose–Vascular Axis: Implications for Vascular Dysfunction in Obesity?
por: Jia, Guanghong, et al.
Publicado: (2016)

Commentary: COVID-19 and obesity pandemics converge into a syndemic requiring urgent and multidisciplinary action
por: Hill, Michael A., et al.
Publicado: (2021)

Glucagon-Like Peptide 1 Receptor Activation and Platelet Function: Beyond Glycemic Control
por: Jia, Guanghong, et al.
Publicado: (2016)

The VASP Road to NAFLD: A Macrophage Detour
por: Lastra, Guido, et al.
Publicado: (2015)

Incretin Concepts
por: Bloomgarden, Zachary T.
Publicado: (2010)

Inflammation and incretins
por: Hatwal, Amitabh
Publicado: (2012)

Mineralocorticoid Receptors: An Appealing Target to Treat Coronary Microvascular Dysfunction in Diabetes
por: Bender, Shawn B., et al.
Publicado: (2015)

The potential role of incretin therapy in the hospital setting
por: Macdonald, Jennifer J., et al.
Publicado: (2015)

Incretin-Based Therapies: Viewpoints on the way to consensus
por: Nauck, Michael. A., et al.
Publicado: (2009)

Impact of Incretin-Based Therapies on Adipokines and Adiponectin
por: Yaribeygi, Habib, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4ovg6fp1kmbdaoi03rs1kdf7pm